NasdaqGS:ATRI

Stock Analysis Report

Executive Summary

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide.

Snowflake

Fundamentals

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Atrion's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

ATRI

-0.4%

US Medical Equipment

1.0%

US Market


1 Year Return

14.6%

ATRI

12.8%

US Medical Equipment

6.7%

US Market

Return vs Industry: ATRI exceeded the US Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: ATRI exceeded the US Market which returned 6.7% over the past year.


Share holder returns

ATRIIndustryMarket
7 Day0.7%-0.4%1.0%
30 Day-2.2%-2.7%-1.8%
90 Day-1.2%-0.3%-1.8%
1 Year15.4%14.6%13.7%12.8%9.1%6.7%
3 Year86.6%82.4%70.0%64.8%46.1%36.6%
5 Year155.5%145.2%130.9%105.1%66.9%48.6%

Price Volatility Vs. Market

How volatile is Atrion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atrion undervalued based on future cash flows and its price relative to the stock market?

40.06x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: ATRI ($779.63) is trading above our estimate of fair value ($278.43)

Significantly Undervalued: ATRI is trading above our estimate of fair value.


Price Based on Earnings

PE vs Industry: ATRI is good value based on its PE Ratio (40.1x) compared to the Medical Equipment industry average (40.1x).

PE vs Market: ATRI is poor value based on its PE Ratio (40.1x) compared to the US market (17.5x).


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate ATRI's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: ATRI is overvalued based on its PB Ratio (6.4x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Atrion expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

-3.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: ATRI's earnings are forecast to decline over the next 3 years (-3.4% per year).

Earnings vs Market: ATRI's earnings are forecast to decline over the next 3 years (-3.4% per year).

High Growth Earnings: ATRI's earnings are forecast to decline over the next 3 years.

Revenue vs Market: Insufficient data to determine if ATRI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ATRI's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if ATRI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Atrion performed over the past 5 years?

6.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ATRI's earnings have grown by 6.3% per year over the past 5 years.

Accelerating Growth: ATRI's earnings growth over the past year (6.4%) exceeds its 5-year average (6.3% per year).

Earnings vs Industry: ATRI earnings growth over the past year (6.4%) underperformed the Medical Equipment industry 28.2%.


Return on Equity

High ROE: ATRI's Return on Equity (16%) is considered low.


Return on Assets

ROA vs Industry: ATRI has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: ATRI's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Atrion's financial position?


Financial Position Analysis

Short Term Liabilities: ATRI's short term assets ($133.1M) exceeds its short term liabilities ($10.9M)

Long Term Liabilities: ATRI's short term assets (133.1M) exceeds its long term liabilities (12.5M)


Debt to Equity History and Analysis

Debt Level: ATRI is debt free.

Reducing Debt: ATRI has not had any debt for past 5 years.

Debt Coverage: ATRI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ATRI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: ATRI has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ATRI's debt is covered by short term assets.


Next Steps

Dividend

What is Atrion's current dividend yield, its reliability and sustainability?

0.80%

Current Dividend Yield


Dividend Yield vs Market

company0.8%marketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: ATRI's dividend (0.8%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: ATRI's dividend (0.8%) is low compared to the top 25% of dividend payers in the US market (3.77%).

Stable Dividend: ATRI is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: ATRI is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: ATRI is not paying a notable dividend for .


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATRI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Atrion's salary, the management and board of directors tenure and is there insider trading?

21.8yrs

Average board tenure


CEO

David Battat (49yo)

8.4yrs

Tenure

US$1,543,530

Compensation

Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a sub ...


CEO Compensation Analysis

Compensation vs. Market: David's total compensation ($USD1.54M) is about average for companies of similar size in the US market ($USD4.08M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Board Age and Tenure

21.8yrs

Average Tenure

70yo

Average Age

Experienced Board: ATRI's board of directors are seasoned and experienced ( 21.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$17,15728 May 19
Ronald Spaulding
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares19
Max PriceUS$903.00
SellUS$163,44328 May 19
Ronald Spaulding
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares181
Max PriceUS$903.00
SellUS$1,536,13229 Nov 18
Jeffery Strickland
EntityIndividual
Role
Chief Financial Officer
VP, CFO
Shares2,000
Max PriceUS$771.00

Ownership Breakdown


Management Team

  • Emile Battat (81yo)

    Executive Chairman

    • Tenure: 21.8yrs
    • Compensation: US$665.27k
  • Jeffery Strickland (60yo)

    VP, CFO

    • Tenure: 22.7yrs
    • Compensation: US$953.00k
  • David Battat (49yo)

    President & CEO

    • Tenure: 8.4yrs
    • Compensation: US$1.54m

Board Members

  • Emile Battat (81yo)

    Executive Chairman

    • Tenure: 21.8yrs
    • Compensation: US$665.27k
  • Hugh Morgan (90yo)

    Independent Director

    • Tenure: 31.8yrs
    • Compensation: US$132.00k
  • John Stupp (69yo)

    Independent Director

    • Tenure: 34.8yrs
    • Compensation: US$140.22k
  • Nicky Spaulding (55yo)

    Independent Director

    • Tenure: 13.7yrs
    • Compensation: US$130.00k
  • Preston Athey (70yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$126.00k

Company Information

Atrion Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atrion Corporation
  • Ticker: ATRI
  • Exchange: NasdaqGS
  • Founded: 1944
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.446b
  • Shares outstanding: 1.85m
  • Website: https://www.atrioncorp.com

Number of Employees


Location

  • Atrion Corporation
  • One Allentown Parkway
  • Allen
  • Texas
  • 75002
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 1969

Biography

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and r ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:12
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)